Dirk BS. , Weir G, Quinton T, Hrytsenko O, and Stanford MM. Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model. Sci Rep. 2021; 11: 4502.
Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, Hirschhorn D, Campesato LF, De Henau O, Gigoux M, Liu C, Mazo G, Deng L, Barker CA, Wolchok JD, and Merghoub T. Targeting phosphatidylserine enhances the anti-tumor response to tumor-directed radiation therapy in pre-clinical model of melanoma. Cell Rep 2021; 34(2): 108620.
Schad S, Hirschhorn-Cymerman D, Budhu S, Zhong H, Yang X, Merghoub T, and Wolchok JD. Phosphatidylserine targeting antibody enhances anti-tumor activity of adoptive cell therapies in a mouse melanoma model. J Immunol 2020, 204 (1 Supplement) 170.5.
Nagata S, Suzuki J, Segawa K, and Fugii T. Exposure of phosphatidylserine on the cell surface. Cell Death and Differentiation 2016; 23: 952–961.
Borisenko GG, Matsura T, Liu S-X, Tyurin VA, Jianfei J, Serinkan FB, Kagan VE. Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cells–existence of a threshold. Arch Biochem Biophys 2003;413(1):41-52.